Brandon D L Marshall1, William C Goedel2, Maximilian R F King2, Alyson Singleton3, David P Durham4, Philip A Chan5, Jeffrey P Townsend6, Alison P Galvani7. 1. Department of Epidemiology, School of Public Health, Brown University, Providence, RI, USA. Electronic address: brandon_marshall@brown.edu. 2. Department of Epidemiology, School of Public Health, Brown University, Providence, RI, USA. 3. Department of Applied Mathematics, Brown University, Providence, RI, USA. 4. Center for Infectious Disease Modeling and Analysis, School of Public Health, Yale University, New Haven, CT, USA. 5. Department of Medicine, Warren Alpert Medical School, Brown University, Providence, RI, USA. 6. Department of Biostatistics, School of Public Health, Yale University, New Haven, CT, USA; Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT, USA; Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA. 7. Center for Infectious Disease Modeling and Analysis, School of Public Health, Yale University, New Haven, CT, USA; Department of Ecology and Evolutionary Biology, Yale University, New Haven, CT, USA; Program in Computational Biology and Bioinformatics, Yale University, New Haven, CT, USA.
Abstract
BACKGROUND: Oral pre-exposure prophylaxis (PrEP) prevents HIV infection in men who have sex with men (MSM); however, adherence is an ongoing concern. Long-acting injectable PrEP is being tested in phase 3 trials and could address challenges associated with adherence. We examined the potential effectiveness of long-acting injectable PrEP compared with oral PrEP in MSM. METHODS: We used an agent-based model to simulate HIV transmission in a dynamic network of 11 245 MSM in Atlanta, GA, USA. We used raw data from studies in macaque models and pharmacokinetic data from safety trials to estimate the time-varying efficacy of long-acting injectable PrEP. The effect of long-acting injectable PrEP on the cumulative number of new HIV infections over 10 years (2015-24) was compared with no PrEP and daily oral PrEP across a range of coverage levels. Sensitivity analyses were done with varying maximum efficacy and drug half-life values. FINDINGS: In the absence of PrEP, the model predicted 2374 new HIV infections (95% simulation interval [SI] 2345-2412) between 2015 and 2024. The cumulative number of new HIV infections was reduced in all scenarios in which MSM received long-acting injectable PrEP compared with oral PrEP. At a coverage level of 35%, compared with no PrEP, long-acting injectable PrEP led to a 44% reduction in new HIV infections (1044 new infections averted [95% SI 1018-1077]) versus 33% (792 infections averted [763-821]) for oral PrEP. The relative benefit of long-acting injectable PrEP was sensitive to the assumed efficacy of injections received every 8 weeks, discontinuation rates, and terminal drug half-life. INTERPRETATION: Long-acting injectable PrEP has the potential to produce larger reductions in HIV transmission in MSM than oral PrEP. However, the real-world, population-level impact of this approach will depend on uptake of this prevention method and its effectiveness, as well as retention of patients in clinical care. FUNDING: National Institute on Drug Abuse and National Institute of Mental Health.
BACKGROUND: Oral pre-exposure prophylaxis (PrEP) prevents HIV infection in men who have sex with men (MSM); however, adherence is an ongoing concern. Long-acting injectable PrEP is being tested in phase 3 trials and could address challenges associated with adherence. We examined the potential effectiveness of long-acting injectable PrEP compared with oral PrEP in MSM. METHODS: We used an agent-based model to simulate HIV transmission in a dynamic network of 11 245 MSM in Atlanta, GA, USA. We used raw data from studies in macaque models and pharmacokinetic data from safety trials to estimate the time-varying efficacy of long-acting injectable PrEP. The effect of long-acting injectable PrEP on the cumulative number of new HIV infections over 10 years (2015-24) was compared with no PrEP and daily oral PrEP across a range of coverage levels. Sensitivity analyses were done with varying maximum efficacy and drug half-life values. FINDINGS: In the absence of PrEP, the model predicted 2374 new HIV infections (95% simulation interval [SI] 2345-2412) between 2015 and 2024. The cumulative number of new HIV infections was reduced in all scenarios in which MSM received long-acting injectable PrEP compared with oral PrEP. At a coverage level of 35%, compared with no PrEP, long-acting injectable PrEP led to a 44% reduction in new HIV infections (1044 new infections averted [95% SI 1018-1077]) versus 33% (792 infections averted [763-821]) for oral PrEP. The relative benefit of long-acting injectable PrEP was sensitive to the assumed efficacy of injections received every 8 weeks, discontinuation rates, and terminal drug half-life. INTERPRETATION: Long-acting injectable PrEP has the potential to produce larger reductions in HIV transmission in MSM than oral PrEP. However, the real-world, population-level impact of this approach will depend on uptake of this prevention method and its effectiveness, as well as retention of patients in clinical care. FUNDING: National Institute on Drug Abuse and National Institute of Mental Health.
Authors: Chris Beyrer; Stefan D Baral; Frits van Griensven; Steven M Goodreau; Suwat Chariyalertsak; Andrea L Wirtz; Ron Brookmeyer Journal: Lancet Date: 2012-07-20 Impact factor: 79.321
Authors: Samuel M Jenness; Steven M Goodreau; Eli Rosenberg; Emily N Beylerian; Karen W Hoover; Dawn K Smith; Patrick Sullivan Journal: J Infect Dis Date: 2016-07-14 Impact factor: 5.226
Authors: Said A Hassounah; Thibault Mesplède; Peter K Quashie; Maureen Oliveira; Paul A Sandstrom; Mark A Wainberg Journal: J Virol Date: 2014-06-11 Impact factor: 5.103
Authors: Eli S Rosenberg; Gregorio A Millett; Patrick S Sullivan; Carlos Del Rio; James W Curran Journal: Lancet HIV Date: 2014-12 Impact factor: 12.767
Authors: Chasity D Andrews; William R Spreen; Hiroshi Mohri; Lee Moss; Susan Ford; Agegnehu Gettie; Kasi Russell-Lodrigue; Rudolf P Bohm; Cecilia Cheng-Mayer; Zhi Hong; Martin Markowitz; David D Ho Journal: Science Date: 2014-03-04 Impact factor: 47.728
Authors: Robert L Glaubius; Urvi M Parikh; Greg Hood; Kerri J Penrose; Eran Bendavid; John W Mellors; Ume L Abbas Journal: Open Forum Infect Dis Date: 2016-06-16 Impact factor: 4.423
Authors: Sheena McCormack; David T Dunn; Monica Desai; David I Dolling; Mitzy Gafos; Richard Gilson; Ann K Sullivan; Amanda Clarke; Iain Reeves; Gabriel Schembri; Nicola Mackie; Christine Bowman; Charles J Lacey; Vanessa Apea; Michael Brady; Julie Fox; Stephen Taylor; Simone Antonucci; Saye H Khoo; James Rooney; Anthony Nardone; Martin Fisher; Alan McOwan; Andrew N Phillips; Anne M Johnson; Brian Gazzard; Owen N Gill Journal: Lancet Date: 2015-09-09 Impact factor: 79.321
Authors: Ashley L Buchanan; S Bessey; William C Goedel; Maximilian King; Eleanor J Murray; Samuel R Friedman; M Elizabeth Halloran; Brandon D L Marshall Journal: Am J Epidemiol Date: 2021-05-04 Impact factor: 4.897
Authors: Kevin M Maloney; Adrien Le Guillou; Robert A Driggers; Supriya Sarkar; Emeli J Anderson; Amyn A Malik; Samuel M Jenness Journal: J Infect Dis Date: 2021-01-04 Impact factor: 5.226
Authors: William C Goedel; Amy S Nunn; Philip A Chan; Dustin T Duncan; Katie B Biello; Steven A Safren; Brandon D L Marshall Journal: AIDS Date: 2019-11-01 Impact factor: 4.177
Authors: Philip A Chan; William C Goedel; Amy S Nunn; Genoviva Sowemimo-Coker; Omar Galárraga; Mattia Prosperi; Rupa Patel; Leandro Mena; Madeline C Montgomery; Brandon D L Marshall Journal: AIDS Patient Care STDS Date: 2019-10 Impact factor: 5.078
Authors: Anthony Todd Fojo; Melissa Schnure; Parastu Kasaie; David W Dowdy; Maunank Shah Journal: Ann Intern Med Date: 2021-09-21 Impact factor: 25.391
Authors: Anthony Nguyen; Emmanuel Fulgence Drabo; Wendy H Garland; Corrina Moucheraud; Ian W Holloway; Arleen Leibowitz; Sze-Chuan Suen Journal: AIDS Patient Care STDS Date: 2022-08 Impact factor: 5.944
Authors: Aditya S Khanna; John A Schneider; Nicholson Collier; Jonathan Ozik; Rodal Issema; Angela di Paola; Abigail Skwara; Arthi Ramachandran; Jeannette Webb; Russell Brewer; William Cunningham; Charles Hilliard; Santhoshini Ramani; Kayo Fujimoto; Nina Harawa Journal: AIDS Date: 2019-10-01 Impact factor: 4.177
Authors: Long Hoang Nguyen; Huong Lan Thi Nguyen; Bach Xuan Tran; Mattias Larsson; Luis E C Rocha; Anna Thorson; Susanne Strömdahl Journal: BMC Infect Dis Date: 2021-05-25 Impact factor: 3.090